US Stock Movement: Korsana surged on September 29 with a Buy rating, $70 price target, and brain drug development.
Bitget异动解读2026/09/29 17:40Korsana September 29 – Major Price Increase Analysis
Keywords: Buy Rating, $70 Price Target, Neurological Drug R&D
1. On September 28, Guggenheim initiated coverage of Korsana with a "Buy" rating and set a $70 price target; this target implies a 125.8% upside from the closing price of $31 on September 25, serving as the main news catalyst for the day.
2. On July 22, the company disclosed that it is a biopharmaceutical company developing therapies for neurodegenerative diseases. Its core candidate, KRSA-028, in combination with the THETA platform, plans to submit an Australian Clinical Trial Notification or New Zealand Clinical Trial Application by the end of 2026, and to file an IND application in the United States in the first quarter of 2027.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only; it does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
